Dabigatran overload in acute kidney injury: haemodialysis or idarucizumab? A case report and proposal for a decisional algorithm

Abstract Dabigatran overload has been reported in acute kidney injury (AKI), leading to occasional major bleeding. Haemodialysis (HD) was the method used for reversing dabigatran anticoagulant effects before the approval of idarucizumab, which is now indicated for dabigatran reversal in major bleedi...

Full description

Saved in:
Bibliographic Details
Published in:Clinical Kidney Journal 2021-02, Vol.14 (2), p.712-714
Main Authors: Galassi, Andrea, Podda, Gianmarco, Monciino, Paola, Stucchi, Andrea, Del Nero, Alberto, Cozzolino, Mario
Format: Article
Language:English
Subjects:
Algorithms
Anticoagulants (Medicine)
Dabigatran etexilate
Dutasteride
Exceptional Cases
Hydrochlorothiazide
Tranexamic acid
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c512t-7520be8aa9e3172096e27ea320d20570c94f6021160837dcb9ccd8093aa6fcb03
cites
container_end_page 714
container_issue 2
container_start_page 712
container_title Clinical Kidney Journal
container_volume 14
creator Galassi, Andrea
Podda, Gianmarco
Monciino, Paola
Stucchi, Andrea
Del Nero, Alberto
Cozzolino, Mario
description Abstract Dabigatran overload has been reported in acute kidney injury (AKI), leading to occasional major bleeding. Haemodialysis (HD) was the method used for reversing dabigatran anticoagulant effects before the approval of idarucizumab, which is now indicated for dabigatran reversal in major bleeding or surgical emergencies. There have been reports of rebound of dabigatran levels following idarucizumab administration in AKI, requiring HD to achieve effective dabigatran clearance. However, a decisional algorithm to individualize treatments for dabigatran overload seems lacking. We present a case of dabigatran accumulation in obstructive AKI with minor bleeding that was successfully treated with HD and tranexamic acid without using idarucizumab, and propose a decision-making algorithm including different pathways in the management of suspected dabigatran overload in AKI.
doi_str_mv 10.1093/ckj/sfaa011
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8173663</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A687661580</galeid><oup_id>10.1093/ckj/sfaa011</oup_id><sourcerecordid>A687661580</sourcerecordid><originalsourceid>FETCH-LOGICAL-c512t-7520be8aa9e3172096e27ea320d20570c94f6021160837dcb9ccd8093aa6fcb03</originalsourceid><addsrcrecordid>eNptUU1r3DAQFaWhCUlOvRdBobdN9LGW7B5alrRNAoFe2rMYS-NdbWzJSHZgc-pPr8KmSwPRHKSZ9-ZppEfIe84uOGvkpb3fXuYOgHH-hpwItqwXdcXl28OZVcfkPOctK6sgbFm9I8dyyRnXWpyQP9-g9WuYEgQaHzD1ERz1gYKdJ6T33gXclXw7p91nugEcovPQ77LPNCbqHaTZ-sd5gPYrXVELGWnCMaaJQnB0THGMGXraFTJQh9ZnH0MpQL-OyU-b4YwcddBnPH_eT8nvH99_Xd0s7n5e316t7ha24mJa6EqwFmuABiXXgjUKhUaQgjnBKs1ss-wUE5wrVkvtbNtY6-ryQwCqsy2Tp-TLXnec2wGdxVDe3Jsx-QHSzkTw5iUS_Mas44OpuZZKySLwcS-whh6ND10sNDv4bM1K1VopXtVP11y8wirhcPA2Bux8qb9o-PD_XIeB_llUCJ_2hDiPB5Qz82S_KfabZ_vlX77lorM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Dabigatran overload in acute kidney injury: haemodialysis or idarucizumab? A case report and proposal for a decisional algorithm</title><source>OUP_牛津大学出版社OA刊</source><source>PubMed Central</source><creator>Galassi, Andrea ; Podda, Gianmarco ; Monciino, Paola ; Stucchi, Andrea ; Del Nero, Alberto ; Cozzolino, Mario</creator><creatorcontrib>Galassi, Andrea ; Podda, Gianmarco ; Monciino, Paola ; Stucchi, Andrea ; Del Nero, Alberto ; Cozzolino, Mario</creatorcontrib><description>Abstract Dabigatran overload has been reported in acute kidney injury (AKI), leading to occasional major bleeding. Haemodialysis (HD) was the method used for reversing dabigatran anticoagulant effects before the approval of idarucizumab, which is now indicated for dabigatran reversal in major bleeding or surgical emergencies. There have been reports of rebound of dabigatran levels following idarucizumab administration in AKI, requiring HD to achieve effective dabigatran clearance. However, a decisional algorithm to individualize treatments for dabigatran overload seems lacking. We present a case of dabigatran accumulation in obstructive AKI with minor bleeding that was successfully treated with HD and tranexamic acid without using idarucizumab, and propose a decision-making algorithm including different pathways in the management of suspected dabigatran overload in AKI.</description><identifier>ISSN: 2048-8505</identifier><identifier>EISSN: 2048-8513</identifier><identifier>DOI: 10.1093/ckj/sfaa011</identifier><identifier>PMID: 34101772</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Algorithms ; Anticoagulants (Medicine) ; Dabigatran etexilate ; Dutasteride ; Exceptional Cases ; Hydrochlorothiazide ; Tranexamic acid</subject><ispartof>Clinical Kidney Journal, 2021-02, Vol.14 (2), p.712-714</ispartof><rights>The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. 2020</rights><rights>The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.</rights><rights>COPYRIGHT 2021 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c512t-7520be8aa9e3172096e27ea320d20570c94f6021160837dcb9ccd8093aa6fcb03</citedby><orcidid>0000-0002-8494-6252</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173663/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173663/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34101772$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Galassi, Andrea</creatorcontrib><creatorcontrib>Podda, Gianmarco</creatorcontrib><creatorcontrib>Monciino, Paola</creatorcontrib><creatorcontrib>Stucchi, Andrea</creatorcontrib><creatorcontrib>Del Nero, Alberto</creatorcontrib><creatorcontrib>Cozzolino, Mario</creatorcontrib><title>Dabigatran overload in acute kidney injury: haemodialysis or idarucizumab? A case report and proposal for a decisional algorithm</title><title>Clinical Kidney Journal</title><addtitle>Clin Kidney J</addtitle><description>Abstract Dabigatran overload has been reported in acute kidney injury (AKI), leading to occasional major bleeding. Haemodialysis (HD) was the method used for reversing dabigatran anticoagulant effects before the approval of idarucizumab, which is now indicated for dabigatran reversal in major bleeding or surgical emergencies. There have been reports of rebound of dabigatran levels following idarucizumab administration in AKI, requiring HD to achieve effective dabigatran clearance. However, a decisional algorithm to individualize treatments for dabigatran overload seems lacking. We present a case of dabigatran accumulation in obstructive AKI with minor bleeding that was successfully treated with HD and tranexamic acid without using idarucizumab, and propose a decision-making algorithm including different pathways in the management of suspected dabigatran overload in AKI.</description><subject>Algorithms</subject><subject>Anticoagulants (Medicine)</subject><subject>Dabigatran etexilate</subject><subject>Dutasteride</subject><subject>Exceptional Cases</subject><subject>Hydrochlorothiazide</subject><subject>Tranexamic acid</subject><issn>2048-8505</issn><issn>2048-8513</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNptUU1r3DAQFaWhCUlOvRdBobdN9LGW7B5alrRNAoFe2rMYS-NdbWzJSHZgc-pPr8KmSwPRHKSZ9-ZppEfIe84uOGvkpb3fXuYOgHH-hpwItqwXdcXl28OZVcfkPOctK6sgbFm9I8dyyRnXWpyQP9-g9WuYEgQaHzD1ERz1gYKdJ6T33gXclXw7p91nugEcovPQ77LPNCbqHaTZ-sd5gPYrXVELGWnCMaaJQnB0THGMGXraFTJQh9ZnH0MpQL-OyU-b4YwcddBnPH_eT8nvH99_Xd0s7n5e316t7ha24mJa6EqwFmuABiXXgjUKhUaQgjnBKs1ss-wUE5wrVkvtbNtY6-ryQwCqsy2Tp-TLXnec2wGdxVDe3Jsx-QHSzkTw5iUS_Mas44OpuZZKySLwcS-whh6ND10sNDv4bM1K1VopXtVP11y8wirhcPA2Bux8qb9o-PD_XIeB_llUCJ_2hDiPB5Qz82S_KfabZ_vlX77lorM</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Galassi, Andrea</creator><creator>Podda, Gianmarco</creator><creator>Monciino, Paola</creator><creator>Stucchi, Andrea</creator><creator>Del Nero, Alberto</creator><creator>Cozzolino, Mario</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8494-6252</orcidid></search><sort><creationdate>20210201</creationdate><title>Dabigatran overload in acute kidney injury: haemodialysis or idarucizumab? A case report and proposal for a decisional algorithm</title><author>Galassi, Andrea ; Podda, Gianmarco ; Monciino, Paola ; Stucchi, Andrea ; Del Nero, Alberto ; Cozzolino, Mario</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c512t-7520be8aa9e3172096e27ea320d20570c94f6021160837dcb9ccd8093aa6fcb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Algorithms</topic><topic>Anticoagulants (Medicine)</topic><topic>Dabigatran etexilate</topic><topic>Dutasteride</topic><topic>Exceptional Cases</topic><topic>Hydrochlorothiazide</topic><topic>Tranexamic acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Galassi, Andrea</creatorcontrib><creatorcontrib>Podda, Gianmarco</creatorcontrib><creatorcontrib>Monciino, Paola</creatorcontrib><creatorcontrib>Stucchi, Andrea</creatorcontrib><creatorcontrib>Del Nero, Alberto</creatorcontrib><creatorcontrib>Cozzolino, Mario</creatorcontrib><collection>OUP_牛津大学出版社OA刊</collection><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical Kidney Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Galassi, Andrea</au><au>Podda, Gianmarco</au><au>Monciino, Paola</au><au>Stucchi, Andrea</au><au>Del Nero, Alberto</au><au>Cozzolino, Mario</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dabigatran overload in acute kidney injury: haemodialysis or idarucizumab? A case report and proposal for a decisional algorithm</atitle><jtitle>Clinical Kidney Journal</jtitle><addtitle>Clin Kidney J</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>14</volume><issue>2</issue><spage>712</spage><epage>714</epage><pages>712-714</pages><issn>2048-8505</issn><eissn>2048-8513</eissn><abstract>Abstract Dabigatran overload has been reported in acute kidney injury (AKI), leading to occasional major bleeding. Haemodialysis (HD) was the method used for reversing dabigatran anticoagulant effects before the approval of idarucizumab, which is now indicated for dabigatran reversal in major bleeding or surgical emergencies. There have been reports of rebound of dabigatran levels following idarucizumab administration in AKI, requiring HD to achieve effective dabigatran clearance. However, a decisional algorithm to individualize treatments for dabigatran overload seems lacking. We present a case of dabigatran accumulation in obstructive AKI with minor bleeding that was successfully treated with HD and tranexamic acid without using idarucizumab, and propose a decision-making algorithm including different pathways in the management of suspected dabigatran overload in AKI.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>34101772</pmid><doi>10.1093/ckj/sfaa011</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-8494-6252</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2048-8505
ispartof Clinical Kidney Journal, 2021-02, Vol.14 (2), p.712-714
issn 2048-8505
2048-8513
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8173663
source OUP_牛津大学出版社OA刊; PubMed Central
subjects Algorithms
Anticoagulants (Medicine)
Dabigatran etexilate
Dutasteride
Exceptional Cases
Hydrochlorothiazide
Tranexamic acid
title Dabigatran overload in acute kidney injury: haemodialysis or idarucizumab? A case report and proposal for a decisional algorithm
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T07%3A19%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dabigatran%20overload%20in%20acute%20kidney%20injury:%20haemodialysis%20or%20idarucizumab?%20A%20case%20report%20and%20proposal%20for%20a%20decisional%20algorithm&rft.jtitle=Clinical%20Kidney%20Journal&rft.au=Galassi,%20Andrea&rft.date=2021-02-01&rft.volume=14&rft.issue=2&rft.spage=712&rft.epage=714&rft.pages=712-714&rft.issn=2048-8505&rft.eissn=2048-8513&rft_id=info:doi/10.1093/ckj/sfaa011&rft_dat=%3Cgale_pubme%3EA687661580%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c512t-7520be8aa9e3172096e27ea320d20570c94f6021160837dcb9ccd8093aa6fcb03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/34101772&rft_galeid=A687661580&rft_oup_id=10.1093/ckj/sfaa011&rfr_iscdi=true